Maraviroc: The first of a new class of antiretroviral agents

Rodger D. MacArthur, Richard M. Novak

Research output: Contribution to journalReview articlepeer-review

180 Scopus citations


Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target. Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells. In this review, we include the details of the discoveries that led to the development of this drug. The drug's pharmacology, including pharmacokinetics and drug interactions, is discussed, as are the clinical efficacy studies that led to licensure. HIV-1 mechanisms of resistance to maraviroc, assays to determine viral coreceptor use (tropism), drug safety, and clinical use of maraviroc are discussed at length.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalClinical Infectious Diseases
Issue number2
StatePublished - Jul 15 2008
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Maraviroc: The first of a new class of antiretroviral agents'. Together they form a unique fingerprint.

Cite this